MIRM.US Mirum Pharmaceuticals Inc

Healthcare Biotechnology USA Stocks
91.58 USD
Close of Nov 17, 2026
63.23 130.00
Market cap
USD 5.98B
P/E
-
P/B
26.59x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is MIRM.US undervalued?

Graham number

The Graham number of Mirum Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Mirum Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Mirum Pharmaceuticals Inc yet.

Mirum Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved …

Full company profile